NCT02064413已完成3 期
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 134
- 试验地点
- 20
- 主要终点
- Rate of successful bilateral placement of the ESS310 insert at first attempt in subjects who undergo attempted ESS310 placement
研究概览
简要总结
To evaluate the safety and successful placement rate of Essure Model ESS310 device and any factors that may influence the successful placement rate of this device.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 44 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Females aged range 21 to 44 years
- •Subjects seeking permanent contraception
- •Subjects with body weight within range of 90-300 pounds (40 - 136 kilograms)
- •Subjects for whom medical history indicates bilateral viable and patent fallopian tubes
- •Subjects are able and willing to comply with the protocol required follow-up visits
- •Subjects have fulfilled local requirements for counseling and consent to contraception and sterilization, including any required waiting periods
- •Subjects provide written informed consent prior to enrolment
- •Subjects who have sufficient mental capacity to understand the informed consent form (ICF), comply with the protocol requirements, and provide clinically relevant and reliable feedback regarding their experience implant and subsequent wearing of the device
- •Subjects who agree that anonymized personal data will be made available to study Sponsor and requisite regional and international regulatory bodies
排除标准
- •Subjects suspected of being or confirmed pregnant
- •Subjects post-partum or undergone pregnancy termination ≤6 weeks of scheduled insert placement
- •Subjects who have known proximal tubal occlusion in either fallopian tube
- •Subjects who have undergone fallopian tube sterilization procedure
- •Subjects who have had total or partial salpingectomies
- •Subjects diagnosed with tubal, endometrial, or myometrial pathology which may prevent fallopian tube ostia access
- •Subjects diagnosed with unicornuate uterus
- •Subjects diagnosed with active or currently being treated upper or lower pelvic infection
- •Subjects with gynecologic malignancy
- •Subjects who are currently taking corticosteroids
- •Subjects with a known allergy to all contrast media available for use in HSG (Hysterosalpingogram)
- •Subjects scheduled to undergo concomitant intrauterine procedures at the time of insert placement (e.g., endometrial ablation, fibroid resection by hysteroscopy, endometrial polypectomy). Intrauterine device removal is not considered a concomitant procedure.
- •Subjects with any general health condition or systemic disease that may represent, in the opinion of the physician, a potential increased risk associated with device use or pregnancy
- •Subjects with a close affiliation with the investigational site, e.g. closely related or affiliated with the investigator (such as dependent, employee or student of the investigational site, or sponsor's staff)
结局指标
主要结局
Rate of successful bilateral placement of the ESS310 insert at first attempt in subjects who undergo attempted ESS310 placement
时间窗: Day 1
次要结局
- Successful bilateral placement rate of the ESS310 insert at first attempt in all subjects who undergo hysteroscopy with the intent of having bilateral ESS310 placement(Day 1)
- Number of participants with Adverse device effects (ADE) as a measure of safety and tolerability(1 week)
- Evaluation of investigator questionnaire regarding ESS310 design and usability(Day 1)
- Evaluation of investigator questionnaire regarding potential factors predictive of failure to achieve bilateral placement of the ESS310 insert at first attempt(Day 1)
- Hysteroscopy time to perform the procedure(Day 1)
- Number of participants with Adverse procedure-related events as a measure of safety and tolerability(Day 1, 1 week)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
不适用
The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in WomenContraceptionNCT01861886Bayer73
已完成
3 期
Methotrexate - Inadequate Response Device Sub-StudyRheumatoid Arthritis (RA)NCT01173120Bristol-Myers Squibb62
已完成
3 期
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial FibrillationAtrial FibrillationNCT03683030Biosense Webster, Inc.397
招募中
不适用
Improvement of Symptoms After Removal of the Essure® Contraceptive ImplantImplant ComplicationContraceptive Device ComplicationsNCT06355713Hospices Civils de Lyon444
已完成
不适用
Clinical Validation Study of the Eximis CS (Contained Segmentation) SystemLaparoscopic Gynecological Surgical ProceduresNCT06572163Eximis Surgical23